LAUSR

Abstract MALIGNANT HYPERTHERMIA (MH) is a well-described and known complication of modern anesthesia, with volatile anesthestics and succinylcholine recognized as triggering agents. Incidence rates vary, but it is estimated to occur in 1:50,000-100,000 individuals undergoing general anesthesia 1. The authors present a case of a patient undergoing a surgical mitral valve replacement who develops Malignant Hyperthermia during separation from cardiopulmonary bypass (CPB}, with urgent return to CPB as a method for the successful treatment of hyperkalemia, hyperthermia, acidemia and hypercarbia. This suggests the potential for CPB or Extracorporeal Membrane Oxygenation (ECMO) as a possible treatment for the symptoms of MH. Consent was obtained from the patient prior to submission of this case report.